Amadeus T Heinz,Friso G J Calkoen,Alexander Derbich,Lea Miltner,Christian Seitz,Michaela Doering,Christiane Braun,Daniel Atar,Michael Schumm,Florian Heubach,Anne-Marie Arendt,Ansgar Schulz,Friedhelm R Schuster,Roland Meisel,Brigitte Strahm,Juergen Finke,Beatrice Heineking,Susanne Stetter,Gerda Silling,Daniel Stachel,Bernd Gruhn,Klaus-Michael Debatin,Juergen Foell,Johannes H Schulte,Wilhelm Woessmann,Christine Mauz-Körholz,Johanna Tischer,Tobias Feuchtinger,Rupert Handgretinger,Peter Lang

Abstract:Therapy-resistant viral reactivations contribute significantly to mortality after hematopoietic stem cell transplantation. Adoptive cellular therapy with virus-specific T cells (VST) has shown efficacy in various single-center trials. However, the scalability of this therapy is hampered by laborious production methods. In this study we describe the in-house production of VST in a closed system (CliniMACS Prodigy® system, Miltenyi Biotec). In addition, we report the efficacy in 26 patients with viral disease following hematopoietic stem cell transplantation in a retrospective analysis (adenovirus, n=7; cytomegalovirus, n=8; Epstein-Barr virus, n=4; multi-viral, n=7). The production of VST was successful in 100% of cases. The safety profile of VST therapy was favorable (n=2 grade 3 and n=1 grade 4 adverse events; all three were reversible). A response was seen in 20 of 26 patients (77%). Responding patients had a significantly better overall survival than patients who did not respond (P<0.001). Virus-specific symptoms were reduced or resolved in 47% of patients. The overall survival of the whole cohort was 28% after 6 months. This study shows the feasibility of automated VST production and safety of application. The scalability of the CliniMACS Prodigy® device increases the accessibility of VST treatment.

Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantation